{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:42Z","timestamp":1786986882026,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.11.009","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T04:59:17Z","timestamp":1264481957000},"page":"2312-2331","source":"Crossref","is-referenced-by-count":55,"special_numbering":"P2","title":["Degarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Michael","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.009_bib1","series-title":"Cancer facts & figures","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib4","series-title":"Firmagon (degarelix) [prescribing information]","year":"2009"},{"key":"10.1016\/j.clinthera.2009.11.009_bib5","series-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics","article-title":"Pituitary hormones and their hypothalamic releasing hormones","author":"Parker","year":"2006"},{"key":"10.1016\/j.clinthera.2009.11.009_bib6","series-title":"Ganirelix acetate injection [prescribing information].","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2008.09.003","article-title":"Will GnRH antagonists improve prostate cancer treatment?","volume":"20","author":"Huhtaniemi","year":"2008","journal-title":"Trends Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2009.11.009_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.301.1.95","article-title":"Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix","volume":"301","author":"Broqua","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2009.11.009_bib9","series-title":"Cetrotide (cetrorelix acetate for injection) [prescribing information]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib10","series-title":"Praecis Pharmaceuticals Incorporated announces strategic restructuring and refocusing of company operations [press release]","year":"2005"},{"key":"10.1016\/j.clinthera.2009.11.009_bib11","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1021\/jm00101a003","article-title":"Gonadotropin-releasing hormone antagonists with N omegatriazolylornithine, -lysine, or -paminophenylalanine residues at positions 5 and 6","volume":"35","author":"Rivier","year":"1992","journal-title":"J Med Chem."},{"key":"10.1016\/j.clinthera.2009.11.009_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/bip.20195","article-title":"Novel gonadotropin-releasing hormone antagonists with substitutions at position 5","volume":"80","author":"Samant","year":"2005","journal-title":"Biopolymers."},{"key":"10.1016\/j.clinthera.2009.11.009_bib13","series-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology","article-title":"Cancer of the prostate","author":"Zelefsky","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib14","first-page":"439","article-title":"High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20\u201369: An autopsy study of 249 cases","volume":"8","author":"Sakr","year":"1994","journal-title":"In Vivo."},{"key":"10.1016\/j.clinthera.2009.11.009_bib16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0140-6736(92)90927-U","article-title":"5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males","volume":"339","author":"Ross","year":"1992","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.11.009_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.amepre.2007.10.003","article-title":"Screening for prostate cancer in U.S. men. ACPM position statement on preventive practice [published correction appears in Am J Prev Med. 2008;34:454]","volume":"34","author":"Lim","year":"2008","journal-title":"Am J Prev Med."},{"key":"10.1016\/j.clinthera.2009.11.009_bib18","series-title":"Urologic Pathology: The Prostate","first-page":"171","article-title":"The Veteran's Administration Cooperative Urologic Re- search Group: Histologic grading and clinical staging of prostatic carcinoma","author":"Gleason","year":"1977"},{"key":"10.1016\/j.clinthera.2009.11.009_bib19","first-page":"15","article-title":"Histologic grade, clinical stage, and patient age in prostate cancer","volume":"7","author":"Gleason","year":"1988","journal-title":"NCI Monogr."},{"key":"10.1016\/j.clinthera.2009.11.009_bib20","series-title":"Harrison's Principles of Internal Medicine","article-title":"Prostate cancer","author":"Scher","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib21","series-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology","article-title":"Molecular biology of prostate cancer","author":"Chen","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJM199202273260906","article-title":"Androgen resistance-the clinical and molecular spectrum","volume":"326","author":"Griffin","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.11.009_bib23","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.juro.2008.07.033","article-title":"A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America","volume":"180","author":"Gittelman","year":"2008","journal-title":"J Urol."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.11.009_bib24","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1200\/jco.2006.24.18_suppl.14516","article-title":"Degarelix: A gonadotropinreleasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients","volume":"24","author":"Gittelman","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.009_bib25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2008.04.065","article-title":"Degarelix: A novel gonadotropin-releasing hormone (GnRH) receptor blocker\u2014results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer","volume":"54","author":"Van Poppel","year":"2008","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2009.11.009_bib26","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2009.11.009_bib27","series-title":"FDA approves Ferring Pharmaceuticals' degarelix (generic name) for treatment of advanced prostate cancer [press release]","year":"2008"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.11.009_bib28","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ejogrb.2004.01.014","article-title":"GnRH analogs: Depot versus short formulations","volume":"115","author":"Dal Prato","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"10.1016\/j.clinthera.2009.11.009_bib29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1358\/dof.2006.031.09.1024366","article-title":"Degarelix acetate","volume":"31","author":"Sorbera","year":"2006","journal-title":"Drugs Future."},{"key":"10.1016\/j.clinthera.2009.11.009_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/jm0003900","article-title":"GnRH antagonists: A new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6","volume":"44","author":"Jiang","year":"2001","journal-title":"J Med Chem."},{"key":"10.1016\/j.clinthera.2009.11.009_bib31","series-title":"Presented at: World Congress on Controversies in Urology","article-title":"Degarelix, a unique, sustainedrelease depot GnRH blocker with a long duration of action","author":"White","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.009_bib32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2125.2006.02820.x","article-title":"Population pharmacokinetic\/ pharmacodynamic (PK\/PD) modelling of the hypothalamic-pituitarygonadal axis following treatment with GnRH analogues","volume":"63","author":"Torn\u00f8e","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.009_bib33","doi-asserted-by":"crossref","first-page":"P87","DOI":"10.1016\/S0009-9236(03)90677-1","article-title":"Population PK\/PD modeling of testosterone (T), LH and dihydrotestosterone (DHT) response to single SC degarelix in male volunteers","volume":"73","author":"Svensson","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.11.009_bib34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1023\/B:PHAM.0000022403.60314.51","article-title":"Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix","volume":"21","author":"Torn\u00f8e","year":"2004","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2009.11.009_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10928-006-9025-1","article-title":"Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker","volume":"33","author":"Jadhav","year":"2006","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2009.11.009_bib36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1124\/jpet.106.112326","article-title":"Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropinreleasing hormone antagonist","volume":"320","author":"Princivalle","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2009.11.009_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1569-9056(05)80908-X","article-title":"Degarelix \u2014 a phase II multicentre, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients","volume":"4","author":"Tammela","year":"2005","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.clinthera.2009.11.009_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.009_bib39","series-title":"Firmagon\u00ae (degarelix) is launched in Europe for the treatment of advanced prostate cancer [press release]","year":"2009"},{"key":"10.1016\/j.clinthera.2009.11.009_bib40","volume":"Vol. 28","year":"2009"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T21:23:33Z","timestamp":1590528213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":37,"alternative-id":["S0149291809003993"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}